Long COVID Patterns in the RECOVER-Adult Study
November 21, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
NovoRapid, Novolog
Synonyms :
insulin aspart
Class :
Antidiabetics, Insulins, Rapid-Acting Insulins
Brand Name :
NovoRapid, Novolog
Synonyms :
insulin aspart
Class :
Antidiabetics, Insulins, Rapid-Acting Insulins
Dosage Forms & StrengthsÂ
Injectable solutionÂ
100 U/mLÂ
Prefilled syringeÂ
100 U/mLÂ
Glycemic control in individuals with diabetes mellitus, encompassing both adults and children, can be enhanced
Administering 0.2–0.6 units per kg per day in divided doses is a common practice, with a prudent approach recommending doses within the range of 0.2–0.4 units per kg per day to mitigate the risk of hypoglycemia
The daily insulin requirement for total maintenance can vary, typically falling between 0.5 and 1 unit per kg
Non-obese individuals may find a range of 0.4–0.6 units per kg suitable, while obese individuals might require a range of 0.6–1.2 units per kg
Dose Adjustments
Limited data is available
For diabetes that remains inadequately controlled despite efforts in diet, weight loss, exercise, or oral medication, a recommendation is to administer ten units per day subcutaneously (or 0.1–0.2 units per kg per day)
This can be done either in the evening as a single dose or divided every 12 hours using long-acting or intermediate insulin (such as NPH) before bedtime
Alternatively, regular insulin or rapid-acting insulin (such as aspart insulin) before meals is also suggested
Dose Adjustments
Limited data is available
Dosage Forms & StrengthsÂ
Injectable solutionÂ
100 U/mLÂ
Prefilled syringeÂ
100 U/mLÂ
Enhanced glycemic control is observed in individuals with diabetes mellitus, encompassing both adults and children
Safety and efficacy are not seen in pediatrics < 2 years
In periods of growth spurts, adolescents might require up to 1.2 units per kg per day subcutaneously; otherwise, a daily intake of 0.5–1 unit per kg is recommended
Refer to the adult dosingÂ
may increase the hypoglycemic effect of Sodium-Glucose Cotransporter 2 Inhibitors
may increase the Glucose-lowering effect of SGLT2 Inhibitors
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with insulin
may have an increased hypoglycemic effect when combined with insulin
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
may increase the effect of insulins
may increase the effect of insulins
the risk or extent of hypoglycemia may increase when acarbose is combined with insulin aspart
the therapeutic effectiveness of insulin aspart can be decreased when used in conjunction with articaine
methylprednisolone hemisuccinateÂ
When methylprednisolone hemisuccinate is aided with insulin aspart, this leads to elevated hyperglycemia risk
may increase the hypoglycaemic effect
may enhance the hypoglycemic effect of beta blockers
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
the therapeutic effectiveness of insulin aspart can be increased when used in conjunction with acebutolol
the risk or extent of hypoglycemia may increase when acetazolamide is combined with insulin aspart
the risk or extent of hypoglycemia may increase when acetohexamide is combined with insulin aspart
the therapeutic effectiveness of insulin aspart can be decreased when used in conjunction with acetophenazine
the therapeutic effectiveness of insulin aspart can be decreased when used in conjunction with aripiprazole
the therapeutic effectiveness of insulin aspart can be decreased when used in conjunction with aripiprazole lauroxil
the therapeutic effectiveness of insulin aspart can be decreased when used in conjunction with arsenic trioxide
the therapeutic effectiveness of insulin aspart can be decreased when used in conjunction with asenapine
Insulin aspart is a fast-acting insulin analog for diabetes with a slight structural difference for quicker effects. It acts faster than regular human insulin due to a single amino acid substitution in its structure.
Frequency not definedÂ
hollowing or thickening of the skin where the medicine was injectedÂ
low blood sugar, Â
trouble breathing, Â
swelling,Â
swelling in hands and feet, Â
itching, Â
fast heartbeats, Â
shortness of breath, Â
rapid weight gain, Â
lightheadedness, Â
constipation, Â
irregular heartbeats,Â
fluttering in the chest, Â
numbness or tingling,Â
redness or swelling where the injection was given, Â
low potassium, Â
redness, Â
weight gain,Â
skin rash, Â
itchy skin rash over the entire body,Â
constipation, Â
leg cramps, Â
swelling of the tongue or throat, Â
limp feelingÂ
muscle weakness,Â
None
Contraindications/caution:
Contraindications:
Hypersensitivity
Cautions:
Hypoglycemia
Injection Site Reactions
Hypokalemia
Pregnancy category:Â N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:Â
NovoLog (insulin aspart) is an insulin, a hormone naturally produced by your body to reduce glucose (sugar) levels in the blood. Its role involves facilitating the absorption of sugar from the bloodstream after meals, converting it into energy. Additionally, insulin aspart inhibits the liver from producing sugar.Â
Pharmacodynamics:Â
Pharmacological effects similar to those of human insulin include the inhibition of lipolysis, suppression of hepatic glucose production, promotion of peripheral glucose uptake by fat and skeletal muscle tissues, and enhancement of protein synthesis.Â
Animal-based biological assays demonstrate an equivalent glucose-lowering effect compared to regular human insulin. Notably, it exhibits a faster onset and shorter duration of action than regular human insulin, resulting in more significant relative reductions in postprandial blood glucose concentrations.Â
Pharmacokinetics:Â
AbsorptionÂ
The time to achieve peak effect is 1 hourÂ
DistributionÂ
Protein-bound is 0-9%Â
Elimination and ExcretionÂ
The half-life is 81 minutesÂ
It is administered in injection form through subcutaneous and intravenous route.
Generic Name: insulin aspart
Why do we use insulin aspart?
Insulin aspart is a fast-acting insulin analog, used to manage the blood sugar levels in individuals with both type 1 and type 2 diabetes mellitus. Its structure is slightly modified from human insulin by allowing it to act faster after injection.
Here are the key reasons with using insulin aspart:
Rapid Onset: Insulin aspart begins to work within 10-20 minutes after injection and making it ideal for controlling postprandial (after meal) blood sugar spikes.
Short Duration: It has a short duration of action typically 3-5 hours, which reduces the risk of prolonged hypoglycemia.
Convenient for Meal Management: Insulin aspart is often administered before or just after meals which provides flexibility in meal timing and helping to mimic the natural insulin response.
Insulin Pumps: Because of its quick action insulin aspart is often used in continuous subcutaneous insulin infusion (insulin pumps) for tighter glucose control throughout the day.
Compatibility with Basal Insulin: Insulin aspart is commonly used alongside long-acting basal insulins (like insulin glargine or detemir) for complete blood glucose control in diabetic patients.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
